• MicuRx Pharmaceuticals’ new antibacterial drug-related research has been published in international authoritative journals

    MRX-6038 (i.e., MRX-5 project of MicuRx Pharmaceuticals R&D pipeline), a novel bacterial leucine-tRNA synthetase inhibitor, is independently developed by MicuRx Pharmaceuticals, and the related research papers on antibacterial activity against Mycobacterium abscessus was published online on August 15, 2022 in Antimicrobial Agents and Chemotherapy, a journal of the American Society of Microbiology, and selected as an Editor’s Pick among others.

    This study was conducted in collaboration with the research group of Professor Chu Haiqing from Shanghai Pulmonary Hospital and Shanghai MicuRx Pharmaceuticals Co., Ltd. By evaluating the in vitro antibacterial activity of MRX-6038 against 12 nontuberculous mycobacteria and 227 clinical isolates, as well as the in vivo efficacy against Mycobacterium abscessus pulmonary infection in mice model, it is demonstrated that MRX-6038 has excellent anti-Mycobacterium abscessus activity, certain synergistic effect with clarithromycin or azithromycin, and good efficacy against intracellular infection and mouse pulmonary infection. This also means that MRX-6038 holds promise as a potential candidate for the treatment of M. abscessus infection.

    Mycobacterium abscessus, commonly found in soil, dust, and water, is an increasingly recognized human pathogen and is emerging as a major threat. It can lead to a variety of clinical manifestations, and the prevalence is increasing yearly in patient populations with respiratory diseases. It attacks lung tissue, makes it difficult to breathe, and is notorious for its extreme resistance to antibiotics. So, M. abscessus is also known as a “new antibiotic nightmare”. The results of this experiment with MRX-6038 are expected to bring new hope for future anti-infective therapy in humans.

    Focusing on the increasingly toughing problem of bacterial drug resistance worldwide, MicuRx Pharmaceuticals takes the treatment of infectious diseases as the core business, is committed to the study of anti-infective drugs, and actively discovers, develops and commercializes innovative drugs for unmet clinical needs, so as to provide more effective and safer treatment options for the most common and serious drug-resistant bacterial infections in clinical practice. MicuRx Pharmaceuticals prompts better therapy through superior medicine!